The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated
